ALX Oncology Holdings Inc. (NASDAQ:ALXO) Shares Sold by Cubist Systematic Strategies LLC

Cubist Systematic Strategies LLC decreased its holdings in ALX Oncology Holdings Inc. (NASDAQ:ALXO) by 91.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 32,021 shares of the company’s stock after selling 351,491 shares during the period. Cubist Systematic Strategies LLC owned about 0.06% of ALX Oncology worth $53,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also modified their holdings of the business. Bridgeway Capital Management LLC acquired a new position in shares of ALX Oncology in the fourth quarter worth $125,000. Bank of America Corp DE lifted its position in shares of ALX Oncology by 492.9% during the 4th quarter. Bank of America Corp DE now owns 1,035,326 shares of the company’s stock worth $1,729,000 after purchasing an additional 860,703 shares during the last quarter. Almitas Capital LLC acquired a new position in shares of ALX Oncology during the fourth quarter worth $2,042,000. Northern Trust Corp grew its stake in shares of ALX Oncology by 7.3% during the fourth quarter. Northern Trust Corp now owns 343,066 shares of the company’s stock worth $573,000 after purchasing an additional 23,324 shares in the last quarter. Finally, Bank of Nova Scotia acquired a new position in shares of ALX Oncology during the fourth quarter worth $176,000. Institutional investors and hedge funds own 97.97% of the company’s stock.

ALX Oncology Trading Down 1.4%

NASDAQ ALXO opened at $0.43 on Tuesday. The stock has a market capitalization of $23.03 million, a P/E ratio of -0.14 and a beta of 1.21. ALX Oncology Holdings Inc. has a 52-week low of $0.41 and a 52-week high of $15.35. The firm has a 50-day moving average price of $0.57 and a 200 day moving average price of $1.13. The company has a quick ratio of 4.82, a current ratio of 4.82 and a debt-to-equity ratio of 0.07.

ALX Oncology (NASDAQ:ALXO) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by ($0.11). Equities research analysts expect that ALX Oncology Holdings Inc. will post -2.76 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on ALXO shares. UBS Group lowered their target price on shares of ALX Oncology from $4.00 to $2.20 and set a “buy” rating for the company in a research note on Monday, January 27th. Jefferies Financial Group upgraded shares of ALX Oncology from a “hold” rating to a “buy” rating and upped their price objective for the company from $2.00 to $3.00 in a research note on Thursday, March 6th. Stifel Nicolaus decreased their price objective on shares of ALX Oncology from $3.00 to $1.50 and set a “hold” rating for the company in a research note on Friday, March 7th. Piper Sandler upped their target price on shares of ALX Oncology from $8.00 to $9.00 and gave the company an “overweight” rating in a report on Thursday, March 6th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of ALX Oncology in a report on Friday, January 24th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $3.54.

ALX Oncology Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.